Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Company Overview

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Key Stats

• Today's Range: $21.55 to $21.55
• 50-Day Range: $21.38 to $21.55
• 52-Week Range: $2.31 to $21.60
• Volume: N/A
• Average Volume: 1.69 million shs
• Market Capitalization: $1.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.83
• Consensus Rating: Hold

Fusion Pharmaceuticals Stock Analysis - MarketRank™

Fusion Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat, and ranked 948th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Fusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 13 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fusion Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fusion Pharmaceuticals has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FUSN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fusion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Fusion Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for FUSN.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Fusion Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FUSN Stock Analysis - Frequently Asked Questions

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) issued its earnings results on Tuesday, November, 9th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.13. The business had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 48.74%.

When did Fusion Pharmaceuticals IPO?

Fusion Pharmaceuticals (FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FUSN
• CUSIP: N/A
• CIK: 1805890
• Web: fusionpharma.com
• Phone: 289-799-0891
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.83
• High Stock Price Target: $24.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +1.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-94,900,000.00
• Net Margins: -4,136.55%
• Pretax Margin: -5,084.07%
• Return on Equity: -48.74%
• Return on Assets: -36.87%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 10.64
• Quick Ratio: 10.64

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 885.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.07 per share
• Price / Book: 7.02

Miscellaneous

• Outstanding Shares: 85,060,000
• Free Float: 78,468,000
• Market Cap: $1.83 billion
• Optionable: Optionable
• Beta: -0.69